Processa Announces $200M Private Placement And Acquisition Of Vidya Therapeutics BTK Inhibitor VT-7208; Existing Shareholders To Own About 0.9% Fully Diluted

Benzinga Newsdesk www.benzinga.com Neutral 86.4%

Neg 0% Neu 86.4% Pos 0%

Comments

No comments yet. Be the first!